Apr
13
EMEA Meeting Highlights From The Committee For Medicinal Products For Human Use, 18-21 September 2006 – Europe
April 13, 2008 | | Leave a Comment
Initial marketing authorisation application The Committee all for Medicinal Products for Human Use (CHMP) give two buoyant opinion neighbouring to early marketing authorisation applications for fresh analysis option for patients distress from diabetes or from cancer: Byetta (exenatide), from Eli Lilly and Company Limited, received a positive evaluation for the treatment of patients beside type-2 diabetes. EMEA investigation get going on 23 November 2005 with an enmeshed review pervasiveness of 208 days.
Sprycel (dasatinib), from BMS pharma EEIG, received a positive opinion for the treatment of incorrigible myeloid leukaemia in patients with unfriendliness or intolerance to prior psychiatric aid with imatinib mesylate, and acute lymphoblastic leukaemia in patients with resistance or intolerance to prior therapy. Sprycel be the 29th point medicinal providing to receive a positive opinion from the Committee. EMEA review began on 1 February 2006 with an active review time of 177 days.
About the American Pharmacists Association (APhA) The American Pharmacists Association, found in 1852 as the American Pharmaceutical Association, indicate highly built-up than 60,000 practicing pharmacists, pharmaceutical scientists, novice pharmacists, pharmacy technicians, and others interested in advance the profession. APhA, fanatical to helping all pharmacists upgrade medication use and mortgage long-suffering care, is the first-established and largest fellowship of pharmacists in the United States. APhA member dispense care in all practice settings, together with idyllic community pharmacies, hospitals, long-term care services, manage care organization, hospice settings, and the air force.
Extension of testimony The Committee gave positive opinions for applications for extension of indication, adding up new treatment options for once certified pills in the district of cancer, diabetes, easily promulgation and cardiovascular illness: Taxotere (docetaxel), from Aventis Pharma S.A., received a positive opinion to embrace the use of Taxotere in combination with cisplatin and 5-fluorouracil for the induction treatment of patients with inoperable locally advanced squamous cell carcinoma of the fascia and band. Taxotere was hasty granted marketing authorisation in the European Union on 27 November 1995 and is authorised for the treatment of breast cancer, non-small-cell lung cancer, prostate cancer and gastric adenocarcinoma.
Previous study own suggested that brightness divulging and increased vitamin D intake be associated with a reduced stake of firm cancers, particularly cancers involving the digestive system. Thirty account of sunlight exposure for a personage with insubstantial rawhide can give out in the region of 20,000 IU of vitamin D. Recent studies have suggested day after day intake of vitamin D should be increased from 400 IU to 1000 IU.
Noxafil (posaconazole) and Posaconazole SP (posaconazole), from Schering Plough Europe, received a positive opinion to include prophylaxis of meddling fungal infection in high-risk patients and to add treatment of oropharyngeal candidiasis in adults. Noxafil and Posaconazole SP be first granted marketing authorisation in the European Union on 25 October 2005 and be in a jiffy authorised for several invasive fungal infections in adults.
Tracleer (bosentan), from Actelion Registration Ltd, received a positive opinion to extend the indication to pulmonary arterial hypertension patients associated with heritable systemic-to- pulmonary shunt and Eisenmenger’s physiology.Tracleer was first granted marketing authorisation in the European Union on 15 May 2002 and is currently indicate fortreatment of pulmonary arterial hypertension (PAH) in special patient populations with grade-III functional reputation.
New contraindications The Committee recommended to add a contraindication for Ketek (telithromycin) and Levviax (telithromycin), from Aventis Pharma S.A., saw that in patients with utterly impair renal and/or hepatic function the two medicinal products should not be administered concomitantly with fit CYP3A4 inhibitors, such as protease inhibitors or ketoconazole. Ketek and Levviax were first granted marketing authorisation on 9 July 2001 and are currently authorised for a digit of respiratory-tract infections.
Summaries of opinions for all products mention above are reachable and can be found here.
Referral procedures concluded The Committee concluded a referral path for Glucomed (glucosamine hydrochloride) and associated name, from Navamedic ASA, recommend the granting of a marketing authorisation for the relief of symptom in placid to clement osteoarthritis of the knees. The procedure was initiate under Article 29 of the Community attitude on human medicinal products (Directive 2001/83/EC as amended) because of tension in relation to the benefit-risk profile here indication among the Member States during the pooled naming procedure.
The Committee concluded a referral procedure for Agopton (lansoprazole) and associated names, from Takeda Pharma GmbH, with a proposition to harmonise the product decline talk, in odd cathartic indication and posology, across the EU. The procedure was initiated via Germany under Article 30 of the Community code on human medicinal products (Directive 2001/83/EC as amended), which is trigger modernized to harmonise difference linking internally authorised product information across the EU.
Referral procedures started The European Commission ask the Committee to ogle the risk-benefit profile of veralipride-containing medicinal products. This pursue concern regarding psychiatric and neurological reaction account with veralipride. The procedure was initiated under Article 31 of Directive 2001/83/EC as amended. Veralipride is indicated for the treatment of roasting flush and psycho-functional symptoms such as anxiety, devaluation or spitefulness of confirmed menopause.
The Committee started a referral procedure for a generic medicinal product call Simvastatine (simvastatine) from Neo Pharma Ltd because of concerns unbroken the security of a bioequivalence den nearly new to embody comparability with the originator product. The procedure was initiated by the Netherlands under Article 36 of the Community code on human medicinal products (Directive 2001/83/EC as amended). Article 36 procedures are initiated where on earth a Member State consider that within are common people gusto issues relating to a product that may oblige regulatory endeavour.
A more detailed CHMP university house of representatives report will be published shortly.
Comments
Create a free edublog to get your own comment avatar (and more!)You must be logged in to post a comment.
